Elephas Biosciences develops a technology platform to assess how live tumor cells respond to cancer therapies. Leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, the company offers the elive™ platform. This tool allows medical oncologists to visualize tumor responses before treatment and assists pharmaceutical R&D teams in predicting immunotherapy response from live tumor biopsies. By maintaining and profiling live human tissue in its native biological context, Elephas supports drug development and clinical decision-making within the oncology sector through a B2B service model.